AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32333207 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living with HIV who do not know their status
Number of subjects: 435
Study 32333591 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (Cholinesterase Inhibitor) started at 5 mg daily, increased to 10 mg daily if tolerated, maintained for 52 weeks.
Number of subjects: 100
Study 32333591 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in UPSIT score from 0 to 8 weeks with Donepezil treatment.
Number of subjects: 100
Study 32333733 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation procedure
Number of subjects: 101
Study 32333763 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP: 25:45:30% energy from protein:carbohydrate:fat)
Number of subjects: 38
Study 32333763 — intervention group
Group type: COMPARATOR
Intervention: Medium protein diet (MP: 15:55:30% of energy from protein:carbohydrate:fat)
Number of subjects: 38
Study 32333763 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocannabinoid concentrations (AEA, OEA, PEA, PREG)
Number of subjects: 38
Study 32333763 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocannabinoid 2-AG
Number of subjects: 38
Study 32333853 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for 18 months after initial 6 months treatment
Number of subjects: 371
Study 32333853 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 months after initial 6 months treatment
Number of subjects: 371
Study 32333853 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of PVOI to HERDOO2, DASH, and updated Vienna scores
Number of subjects: 371
Study 32333930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Efficiency (SE)
Number of subjects: 209
Study 32333930 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Time (TST)
Number of subjects: 209
Study 32334566 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum HDL < 1.03 mmol/L
Number of subjects: 74284
Study 32334566 — intervention group
Group type: COMPARATOR
Intervention: Preoperative serum HDL > 1.03 mmol/L
Number of subjects: 74284
Study 32334566 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL levels categorized as < 0.96, 1.14-1.35, > 1.35
Number of subjects: 74284
Study 32335306 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational unitary manifold (UM) stent graft system
Number of subjects: 44
Study 32335374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib 200 mg plus everolimus 5 mg once daily
Number of subjects: 22
Study 32335374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib 100 mg plus everolimus 5 mg once daily
Number of subjects: 22
Study 32335374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib 150 mg plus everolimus 5 mg once daily
Number of subjects: 22
Study 32335423 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 996
Study 32335515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Myocardial Feature Tracking
Number of subjects: 0
Study 32335525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (measured as VO2peak during a graded cycle ergometer test)
Number of subjects: 30
Study 32335525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2peak)
Number of subjects: 30
Study 32335895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cleansing with povidone-iodine or chlorhexidine solution
Number of subjects: 7038
Study 32336486 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Number of subjects: 2393
Study 32336984 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based recovery-oriented care delivered by trained multidisciplinary community mental health teams.
Number of subjects: 180
Study 32336984 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) - institutional, hospital-based mental health care.
Number of subjects: 180
Study 32336987 — intervention group
Group type: EXPERIMENTAL
Intervention: EMOTION intervention (transdiagnostic indicated preventive cognitive behavioral therapy)
Number of subjects: 795
Study 32336987 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 795
Study 32337054 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNFα therapy
Number of subjects: 310
Study 32337059 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/day of phosphatidylcholine (PPC) as adjunctive treatment to standard care
Number of subjects: 2843
Study 32337094 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib, cetuximab, and bevacizumab (triplet combination)
Number of subjects: 36
Study 32337122 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 32337122 — intervention group
Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 0
Study 32337475 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 g freeze-dried blueberries for 8 weeks
Number of subjects: 52
Study 32337496 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg)
Number of subjects: 431
Study 32337496 — intervention group
Group type: COMPARATOR
Intervention: Physician's Choice of Chemotherapy (PCT)
Number of subjects: 431
Study 32337789 — intervention group
Group type: EXPERIMENTAL
Intervention: Art interventions conducted by professional art pedagogues
Number of subjects: 7
Study 32338094 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inhalers (ICS + LABA)
Number of subjects: 69
Study 32338094 — intervention group
Group type: COMPARATOR
Intervention: Emergency Room visits
Number of subjects: 69
Study 32338094 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 69
Study 32338094 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-related quality-of-life
Number of subjects: 69
Study 32338117 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher carotid artery β-stiffness index
Number of subjects: 84
Study 32338433 — intervention group
Group type: EXPERIMENTAL
Intervention: rAHF 2 mL prophylaxis
Number of subjects: 65
Study 32338433 — intervention group
Group type: EXPERIMENTAL
Intervention: rAHF 2 mL treatment
Number of subjects: 65
Study 32338538 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive sensitization for exercise reinforcement
Number of subjects: 0
Study 32338538 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32338562 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat
Number of subjects: 0
Study 32338619 — intervention group
Group type: EXPERIMENTAL
Intervention: PERSPeCT tailored messaging system (up to 30 emailed messages over 65 days)
Number of subjects: 119
Study 32338619 — intervention group
Group type: EXPERIMENTAL
Intervention: PERSPeCT tailored messaging system
Number of subjects: 119
Study 32338619 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort of white people who smoke (control group)
Number of subjects: 119
Study 32338621 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program driven by a tablet app and remote coaching (12-week program, exercises at least 5 days a week)
Number of subjects: 15
Study 32338621 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program driven by a tablet app and remote coaching
Number of subjects: 15
Study 32338621 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 15
Study 32339189 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy
Number of subjects: 188
Study 32339337 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed routine ultrasound examination
Number of subjects: 255
Study 32339337 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted prenatal imaging in known cases of fetal infection
Number of subjects: 255
Study 32339337 — intervention group
Group type: COMPARATOR
Intervention: Non-specific infection-related ultrasound findings
Number of subjects: 255
Study 32339368 — intervention group
Group type: EXPERIMENTAL
Intervention: Yescarta (axicabtagene ciloleucel)
Number of subjects: 0
Study 32340508 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 32340734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided brachial plexus block
Number of subjects: 565
Study 32341039 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h fasting
Number of subjects: 20
Study 32341039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cold exposure (COLD)
Number of subjects: 20
Study 32341039 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutrality (24°C)
Number of subjects: 20
Study 32341039 — intervention group
Group type: COMPARATOR
Intervention: Mild cold (19°C)
Number of subjects: 20
Study 32341140 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in HFrEF patients
Number of subjects: 5414
Study 32341140 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in HFmrEF patients
Number of subjects: 5414
Study 32341140 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in HFpEF patients
Number of subjects: 5414
Study 32341321 — intervention group
Group type: EXPERIMENTAL
Intervention: First-operated eye
Number of subjects: 74
Study 32341321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow-operated eye
Number of subjects: 74
Study 32341578 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 PD-1-edited T cells
Number of subjects: 22
Study 32341691 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 222
Study 32341691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 32342016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) combined with music therapy (10 therapy sessions and related homework)
Number of subjects: 43
Study 32342016 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 43
Study 32342831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran treatment initiated within 14 days of TIA/minor stroke
Number of subjects: 101
Study 32342831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran treatment
Number of subjects: 101
Study 32342838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue surveillance system
Number of subjects: 0
Study 32343050 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic retinal implant (Retina Implant Alpha AMS) with intensive visual training
Number of subjects: 1
Study 32343050 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic retinal implant (Retina Implant Alpha AMS)
Number of subjects: 1
Study 32343050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive visual training
Number of subjects: 1
Study 32343196 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32343248 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health tools including discharge video and checklist
Number of subjects: 510
Study 32343248 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge messaging service
Number of subjects: 510
Study 32343251 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps per day
Number of subjects: 105
Study 32343251 — intervention group
Group type: EXPERIMENTAL
Intervention: Including specific cadence bands and peak cadences
Number of subjects: 105
Study 32343251 — intervention group
Group type: EXPERIMENTAL
Intervention: Children meeting the WHO recommendation of 60 minutes per day of MVPA
Number of subjects: 105
Study 32343312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure in BATpos individuals
Number of subjects: 0
Study 32343312 — intervention group
Group type: COMPARATOR
Intervention: Cold exposure in BATneg individuals
Number of subjects: 0
Study 32343640 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg plus Nivolumab 3 mg/kg
Number of subjects: 50
Study 32343640 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 80 mg plus Nivolumab 3 mg/kg
Number of subjects: 50
Study 32343640 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 120 mg plus Nivolumab 3 mg/kg
Number of subjects: 50
Study 32343796 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical bone marrow transplantation (BMT) with intensive graft-versus-host disease (GVHD) prophylaxis including posttransplantation cyclophosphamide.
Number of subjects: 74
Study 32343796 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical BMT with posttransplant cyclophosphamide
Number of subjects: 74
Study 32343796 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical BMT with 400 cGy total body irradiation
Number of subjects: 74
Study 32343796 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical BMT with increased total body irradiation dose to 400 cGy
Number of subjects: 74
Study 32344248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 255
Study 32344296 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (±5% between diagnosis and post-treatment)
Number of subjects: 993
Study 32344296 — intervention group
Group type: COMPARATOR
Intervention: Weight gain or stability
Number of subjects: 993
Study 32345039 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting distal-to-aortic coronary pressure ratio (Pd/Pa) ≤0.92
Number of subjects: 4707
Study 32345039 — intervention group
Group type: COMPARATOR
Intervention: Hyperemic fractional flow reserve (FFR) ≤0.80
Number of subjects: 4707
Study 32345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors assessment
Number of subjects: 0
Study 32345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary capacity assessment
Number of subjects: 0
Study 32345378 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 506
Study 32345378 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg (UK subgroup)
Number of subjects: 506
Study 32345417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 50
Study 32346071 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/smq on days 1, 8, 15 every 4 weeks up to six cycles, progressive disease or intolerable toxicity
Number of subjects: 68
Study 32346071 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 68
Study 32346484 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based prehabilitation exercise intervention (increasing daily step-count during and after NAC)
Number of subjects: 40
Study 32346484 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based prehabilitation exercise intervention
Number of subjects: 40
Study 32346485 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive menstrual health intervention program including training teachers, drama skit, menstrual kit training, pain relief guidance, and WASH improvements.
Number of subjects: 450
Study 32346485 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive menstrual health intervention program
Number of subjects: 450
Study 32346486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 82
Study 32346907 — intervention group
Group type: EXPERIMENTAL
Intervention: TST (Total Sleep Time)
Number of subjects: 22
Study 32346907 — intervention group
Group type: EXPERIMENTAL
Intervention: AAC (Activity during Sleep)
Number of subjects: 22
Study 32347439 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective contraception
Number of subjects: 0
Study 32347439 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) visits
Number of subjects: 0
Study 32347439 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for symptomatic children under five
Number of subjects: 0
Study 32347554 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside handover
Number of subjects: 774
Study 32347554 — intervention group
Group type: COMPARATOR
Intervention: Traditional handover
Number of subjects: 774
Study 32347804 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention
Number of subjects: 9
Study 32347804 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring smartphone app and coaching calls
Number of subjects: 9
Study 32347917 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) imaging
Number of subjects: 26
Study 32347917 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of autofluorescence
Number of subjects: 26
Study 32347917 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal hypoplasia
Number of subjects: 26
Study 32347984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Number of subjects: 1984
Study 32347984 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy
Number of subjects: 1984
Study 32348254 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioTracker (CART)
Number of subjects: 100
Study 32348254 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulse oximeter
Number of subjects: 100
Study 32348254 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects with sinus rhythm)
Number of subjects: 100
Study 32348281 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive
Number of subjects: 82
Study 32348281 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit
Number of subjects: 82
Study 32348281 — intervention group
Group type: COMPARATOR
Intervention: GetActive and GetActive-Fitbit
Number of subjects: 82
Study 32348286 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-HD (digital smoking cessation program with additional content specific to heavy drinking)
Number of subjects: 83
Study 32348286 — intervention group
Group type: COMPARATOR
Intervention: EX-S (standard digital smoking cessation program)
Number of subjects: 83
Study 32348286 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-HD and EX-S (both conditions)
Number of subjects: 83
Study 32348286 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-HD
Number of subjects: 83
Study 32348346 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz STN DBS
Number of subjects: 0
Study 32348346 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 Hz STN DBS
Number of subjects: 0
Study 32348346 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning and barrier course (TBC)
Number of subjects: 0
Study 32348346 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 0
Study 32348643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental disorders
Number of subjects: 5940299
Study 32348643 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorders
Number of subjects: 5940299
Study 32348643 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic mental disorders
Number of subjects: 5940299
Study 32348643 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental disorder
Number of subjects: 5940299
Study 32348643 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic mental disorder
Number of subjects: 5940299
Study 32348643 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 5940299
Study 32349020 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous dose-escalated prostate stereotactic body radiation therapy (target volume received 36.25 Gy/5 fx; target >3 mm from sensitive structures escalated to 50 Gy/5 fx)
Number of subjects: 35
Study 32349020 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous dose-escalated prostate stereotactic body radiation therapy
Number of subjects: 35
Study 32349119 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (8 weeks of open-label treatment)
Number of subjects: 87
Study 32349629 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with blood flow restriction for 12 weeks
Number of subjects: 0
Study 32349629 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32349790 — intervention group
Group type: EXPERIMENTAL
Intervention: iCOPE (interactive computer- and text message-delivered personalized feedback intervention with distress tolerance skills training)
Number of subjects: 0
Study 32349790 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 32349803 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD youths
Number of subjects: 240
Study 32349803 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected siblings of ASD youths
Number of subjects: 240
Study 32349803 — intervention group
Group type: COMPARATOR
Intervention: TDC youths
Number of subjects: 240
Study 32350018 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care protocol implementation
Number of subjects: 140
Study 32350018 — intervention group
Group type: COMPARATOR
Intervention: Retrospective chart reviews
Number of subjects: 140
Study 32350018 — intervention group
Group type: COMPARATOR
Intervention: Pilot phase to validate CODE questionnaire
Number of subjects: 140
Study 32350018 — intervention group
Group type: COMPARATOR
Intervention: Focus group discussions (FGDs)
Number of subjects: 140
Study 32350119 — intervention group
Group type: EXPERIMENTAL
Intervention: One vaccine with peptides in pICLC+IFA
Number of subjects: 27
Study 32350119 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV with peptides+IFA
Number of subjects: 27
Study 32350119 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccines containing pICLC
Number of subjects: 27
Study 32350119 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV with peptides in IFA
Number of subjects: 27
Study 32350119 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV with IFA and peptides
Number of subjects: 27
Study 32350119 — intervention group
Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 27
Study 32350119 — intervention group
Group type: COMPARATOR
Intervention: Skin injected with IFA without peptides
Number of subjects: 27
Study 32350338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia Severity Rating Scale (DSRS)
Number of subjects: 0
Study 32350338 — intervention group
Group type: COMPARATOR
Intervention: Pharyngeal electrical stimulation
Number of subjects: 0
Study 32350529 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric treatment (antibiotics and/or antifungals)
Number of subjects: 303
Study 32350529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate prescriptions
Number of subjects: 303
Study 32350529 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-diagnosed cause of vaginitis
Number of subjects: 303